Cairo and colleagues developed a CAR NK cell targeting ROR1 and demonstrated the anti-tumor efficacy of the combination of an oncolytic virus engineered to secrete IL-21 (C021) with anti-ROR1-CAR-NK cells against NB. This evidence concerns the gene ROR1 and neoplasm.